Search results
Minnesota Justices Question State’s Taxation of Drug Rebates
Bloomberg Law· 6 days agoThree Minnesota Supreme Court justices at arguments Monday seemed likely to agree with a wholesale drug distributor that the state’s $500,000 tax bill improperly characterized ...
Viking Therapeutics Stock Crumbles Despite Potential 'Best-In-Class' Liver Disease Drug
Investor's Business Daily· 5 days agoThe company is also working on weight-loss drugs. "Given the unprecedented market opportunity in...
DC Circuit Affirms 340B Program Does Not Prohibit All Drug Manufacturer Distribution Restrictions |...
JD Supra· 7 days agoIn what is being touted as a significant win for pharmaceutical drug manufacturers, the DC Circuit affirmed on May 21, 2024 that Section 340B of the Public Health Service ...
Prescription for trouble: Pharmacists say benefit managers are driving pharmacy closures
Louisiana Illuminator via Yahoo News· 7 days agoIn 1977, Bob Schreiber became the owner of Burns Pharmacy in Morrisville, Pennsylvania. For most of...
Viking's MASH drug scored where Madrigal's didn't, but shares fall on lack of direction
FierceBiotech· 5 days agoViking Therapeutics is pulling up some extra long boats full of reasons the metabolic...
JD Supra: Better Health Care Newsletter
JD Supra· 3 days agoFederal officials have capped the cost of insulin at $35 a month. For now, that gives relief only to patients 65 and older covered by Medicare. Big Pharma in recent years has flouted that charitable intent.
AbbVie's tight grip on Humira market raises concerns about biosimilars
Reuters via Yahoo News· 2 days agoAbbVie’s top-selling arthritis drug Humira has held onto more than 80% of patients after facing nine...
Our opinion: State must pursue PBM reform
Warren Times Observer· 7 days agoIt’s easy for our eyes to glass over when we hear state legislators are discussing legislation to reform the contract process between pharmacies and drug companies. Known ...
New Jersey Statutory Update Part I | JD Supra
JD Supra· 4 days agoLast year was no different, and the discussion below highlights some of those statutes, such as statutes further regulating pharmacy benefit managers, requiring manufacturers to report an increase ...
Medicare Part D Plans Poorly Cover Adalimumab Biosimilars
Medscape· 4 days agoThis narrow coverage limits the cost-saving potential of these biosimilar competitors, expert said.
